Wegener’s Small Vessel Vasculitis
Overview
Wegener’s small vessel vasculitis (also called granulomatosis with polyangiitis, GPA) is a rare autoimmune disorder in which inflammation attacks the walls of small‑ and medium‑sized blood vessels. The disease can cause necrotizing granulomas—clusters of inflamed immune cells—that most often involve the upper airway, lower respiratory tract, and kidneys. When it primarily affects the tiny vessels of the lung and kidney, it is sometimes referred to as “small‑vessel” GPA.
- Incidence: About 3–4 new cases per million people per year in the United States and Europe.1
- Prevalence: Approximately 20–30 cases per million population.2
- Age & gender: Most common in adults aged 40‑70; men are slightly more frequently affected (male : female ≈ 1.2 : 1).3
- Geography: Slightly higher rates in Northern Europe and North America; rare in children (<10 % of cases).4
Symptoms
Because GPA can involve multiple organ systems, symptoms vary widely. Below is a comprehensive list, grouped by the most commonly affected regions.
Respiratory tract
- Chronic sinusitis – persistent nasal congestion, facial pain, or nosebleeds.
- Nasopharyngeal ulceration – painful sores in the nasal cavity, often leading to crusting.
- Otitis media or mastoiditis – ear pain or hearing loss.
- Cough – dry or productive, may be accompanied by blood‑tinged sputum (hemoptysis).
- Dyspnea – shortness of breath, especially on exertion.
- Chest pain – pleuritic pain from lung inflammation.
Kidney involvement
- Hematuria – blood in urine, often painless.
- Proteinuria – foamy urine indicating protein loss.
- Reduced kidney function – fatigue, swelling (edema) of ankles or face.
General / systemic
- Fever – low‑grade, often intermittent.
- Weight loss & loss of appetite – unexplained, over weeks to months.
- Fatigue – profound, not relieved by rest.
- Muscle & joint aches – arthralgias without swelling.
- Skin lesions – palpable purpura, livedo reticularis, or necrotic ulcers.
- Neuropathy – tingling, numbness, or weakness due to peripheral nerve vasculitis.
Eye involvement (less common)
- Redness, pain, or vision changes from scleritis or orbital inflammation.
Causes and Risk Factors
The exact trigger for GPA remains unknown, but current research points to a combination of genetic susceptibility and environmental factors that provoke an abnormal immune response.
Immunologic mechanisms
- ANCA antibodies – ~90 % of patients have anti‑proteinase‑3 ANCA (PR3‑ANCA) detectable in the blood. These auto‑antibodies activate neutrophils, causing them to adhere to and damage vessel walls.
- Complement pathway activation – contributes to inflammatory cascade.
Genetic predisposition
- Specific HLA‑DPB1 and HLA‑DQ alleles increase risk, though no single gene predicts disease.5
Environmental exposures
- Silica dust – occupational exposure (mining, sandblasting) linked to higher ANCA‑vasculitis rates.6
- Infections – Staphylococcus aureus colonization of the nose correlated with disease relapses.7
- Medications – Rarely, certain drugs (e.g., propylthiouracil, hydralazine) can induce ANCA‑positive vasculitis.
Who is at higher risk?
- Adults aged 40‑70, especially males.
- People with a familial history of autoimmune disease.
- Individuals with chronic nasal carriage of Staphylococcus aureus.
- Workers with prolonged silica exposure.
Diagnosis
Because GPA mimics infections, malignancy, and other vasculitides, a systematic approach is essential.
Clinical assessment
- Detailed history focusing on ENT, pulmonary, renal, and systemic symptoms.
- Physical examination: nasal ulceration, lung findings (crackles), skin lesions, joint tenderness, and neurologic deficits.
Laboratory tests
- ANCA testing – ELISA for PR3‑ANCA (most specific) and MPO‑ANCA (less common in GPA). Positive in 80‑90 % of active disease.8
- Complete blood count – may show anemia or leukocytosis.
- Serum creatinine & eGFR – assess kidney involvement.
- Urinalysis – check for hematuria and proteinuria.
- Inflammatory markers – ESR and CRP are usually elevated.
Imaging studies
- Chest X‑ray or CT scan – nodules, cavitary lesions, or diffuse infiltrates.
- Sinus CT – mucosal thickening, bone erosion, or granulomatous masses.
- Ultrasound or MRI of kidneys in select cases.
Biopsy (gold standard)
Histologic confirmation is required when the diagnosis is uncertain.
- Kidney biopsy – necrotizing crescentic glomerulonephritis without immune complex deposition (“pauci‑immune”).
- Nasal or lung tissue biopsy – necrotizing granulomas with vasculitis.
Classification criteria
The 2022 ACR/EULAR GPA classification criteria assign points based on ANCA status, imaging, and biopsy results; a score ≥5 confirms GPA with >90 % specificity.9
Treatment Options
Therapy aims to induce remission quickly, then maintain disease control while limiting medication toxicity.
Induction therapy (first 3‑6 months)
- High‑dose glucocorticoids – oral prednisone 1 mg/kg/day (max 60 mg) or IV methylprednisolone 500‑1000 mg daily for 3 days in severe cases.10
- Immunosuppressive agents
- Rituximab (anti‑CD20 monoclonal antibody) – 375 mg/m² weekly × 4 or 1 g on days 1 and 15. Equivalent to cyclophosphamide for renal‑ or lung‑life‑threatening disease and preferred in patients desiring fertility preservation.11
- Cyclophosphamide – oral 2 mg/kg/day or IV pulse 15 mg/kg every 2‑3 weeks, adjusted for renal function.
Maintenance therapy (≥12 months)
- Rituximab – 500 mg IV on days 1 and 15 every 6 months, or 1 g every 6 months.
- Azathioprine – 2 mg/kg/day.
- Mycophenolate mofetil – 1‑1.5 g twice daily (alternative for patients intolerant of azathioprine).
- Low‑dose prednisone (≤5 mg/day) is usually continued for the first year, then tapered.
Adjunctive measures
- Trimethoprim‑sulfamethoxazole (TMP‑SMX) – prophylaxis against Staphylococcus aureus colonization reduces relapse rates (especially in PR3‑ANCA positive patients).12
- Vaccinations (influenza, pneumococcal, COVID‑19) – essential before initiating high‑dose immunosuppression.
- Bone protection – calcium, vitamin D, and bisphosphonates if glucocorticoids >3 months.
- Regular monitoring of blood counts, liver function, and renal labs.
Procedural interventions
- Plasmapheresis – considered for severe pulmonary hemorrhage or rapidly progressive glomerulonephritis; evidence is mixed, but may reduce need for dialysis in select patients.13
- Endoscopic sinus surgery – for chronic obstruction or scar tissue after disease control.
Living with Wegener’s Small Vessel Vasculitis
Long‑term management is a partnership between you, your rheumatologist, and other specialists (nephrology, pulmonology, ENT, ophthalmology). Below are practical tips to help maintain quality of life.
Medication adherence
- Use a weekly pill organizer and set alarms for oral meds.
- Keep a medication list handy for every medical encounter.
- Report side effects promptly—especially signs of infection, bruising, or abnormal labs.
Monitoring & follow‑up
- Blood work every 2‑4 weeks during induction, then every 3‑6 months on maintenance.
- Urine analysis at each visit to catch early renal relapse.
- Chest X‑ray or CT if you develop new cough, hemoptysis, or dyspnea.
- ENT evaluation every 6‑12 months, even if symptoms improve.
Lifestyle adaptations
- Stay hydrated – helps kidney function.
- Balanced diet – low‑salt, adequate protein (unless told otherwise by a nephrologist).
- Exercise – low‑impact activities (walking, swimming) improve fatigue and bone health.
- Smoking cessation – smoking worsens lung disease and interferes with medication efficacy.
- Stress management – mindfulness, yoga, or counseling can reduce flare triggers.
Fertility & family planning
- Rituximab is considered safer for fertility than cyclophosphamide.
- Discuss contraception and pregnancy plans early; pregnancy is feasible with disease remission and careful medication adjustment.
Psychosocial support
- Connect with patient advocacy groups (e.g., Vasculitis Foundation, ANCA-Associated Vasculitis Association).
- Consider counseling for anxiety or depression, which affect up to 30 % of patients.14
Prevention
Because GPA cannot be “prevented” in the classic sense, strategies focus on reducing triggers and early detection of relapse.
- Screen for Staphylococcus aureus colonization and treat with topical mupirocin if positive.
- Limit occupational silica exposure—use protective masks and adequate ventilation.
- Stay up‑to‑date with vaccinations before starting immunosuppressive therapy.
- Promptly report new ENT, respiratory, or urinary symptoms to your care team.
- Adhere to maintenance therapy even when you feel well; abrupt discontinuation dramatically raises relapse risk.
Complications
If untreated or poorly controlled, GPA can lead to irreversible organ damage.
- End‑stage renal disease (ESRD) – up to 30 % of patients develop chronic kidney failure requiring dialysis or transplant.
- Severe pulmonary hemorrhage – life‑threatening bleeding can cause respiratory failure.
- Upper airway obstruction – subglottic stenosis may need surgical dilation.
- Peripheral neuropathy – can be permanent if vasculitic infarction occurs.
- Ocular complications – scleritis or orbital granulomas may threaten vision.
- Infections – immunosuppression raises risk of bacterial, fungal, and viral infections (e.g., opportunistic pneumonia, shingles).
- Medication toxicity – cyclophosphamide can cause bladder toxicity, infertility, and secondary malignancies; long‑term steroids cause osteoporosis, diabetes, and cataracts.
When to Seek Emergency Care
If you experience any of the following, call 911 or go to the nearest emergency department immediately:
- Sudden, profuse coughing up of blood (hemoptysis).
- Sharp, worsening chest pain or difficulty breathing.
- Rapidly decreasing urine output, swelling of the legs, or new severe flank pain (possible renal flare).
- High fever (>38.5 °C / 101 °F) with chills, especially if you are on immunosuppressants.
- Severe headache, vision loss, or neurological deficits (stroke‑like symptoms).
- Sudden severe abdominal pain (possible bowel ischemia).
- Unexplained, extensive skin bruising or purpura that spreads quickly.
Early treatment of these emergencies can be life‑saving.
Sources: Mayo Clinic, Cleveland Clinic, CDC, NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases, WHO, peer‑reviewed journals (NEJM, Ann Rheum Dis, JAMA). All links accessed July 2024.
```